Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-1.47 Insider Own1.80% Shs Outstand195.21M Perf Week-5.00%
Market Cap259.63M Forward P/E- EPS next Y-0.88 Insider Trans17.41% Shs Float191.69M Perf Month-21.76%
Income-281.30M PEG- EPS next Q-0.31 Inst Own65.90% Short Float25.95% Perf Quarter-19.39%
Sales22.10M P/S11.75 EPS this Y-44.60% Inst Trans-14.40% Short Ratio17.96 Perf Half Y-63.86%
Book/sh-0.30 P/B- EPS next Y38.00% ROA-61.60% Target Price2.25 Perf Year-77.07%
Cash/sh1.05 P/C1.27 EPS next 5Y- ROE- 52W Range1.28 - 8.41 Perf YTD-78.30%
Dividend- P/FCF- EPS past 5Y2.90% ROI-48.50% 52W High-84.19% Beta2.49
Dividend %- Quick Ratio1.20 Sales past 5Y-23.30% Gross Margin92.80% 52W Low3.91% ATR0.09
Employees227 Current Ratio1.30 Sales Q/Q14.50% Oper. Margin- RSI (14)36.71 Volatility7.16% 6.82%
OptionableYes Debt/Eq- EPS Q/Q11.10% Profit Margin- Rel Volume3.14 Prev Close1.35
ShortableYes LT Debt/Eq- EarningsNov 04 AMC Payout- Avg Volume2.77M Price1.33
Recom2.60 SMA20-11.10% SMA50-16.78% SMA200-56.36% Volume8,686,127 Change-1.48%
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Nov-24-08Reiterated Lazard Capital Buy $7
Oct-16-08Initiated Merriman Curhan Ford Buy
Aug-14-08Initiated Banc of America Sec Neutral $7
Aug-06-08Reiterated Lazard Capital Buy $12 → $10
Aug-06-08Downgrade Canaccord Adams Buy → Hold
Jul-08-08Initiated Canaccord Adams Buy $7.30
Dec-07-07Reiterated Fortis Bank Hold $10 → $9
Sep-14-07Initiated Lazard Capital Buy $14
Dec-15-14 01:00AM  Exelixis Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
Dec-05-14 05:16PM  EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online
Dec-02-14 01:29PM  Exelixis Shares Down on COMET-2 Study Results on Cabozantinib Zacks
Dec-01-14 11:37AM  Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study at TheStreet -10.24%
10:23AM  Mid-Morning Market Update: Markets Open Lower; Weatherford To Sell Engineered Chemistry, Drilling Fluid Operations to Berkshire's Lubrizol Benzinga
08:00AM  Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer Business Wire
Nov-25-14 04:05PM  Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 Business Wire
Nov-16-14 04:20AM  Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib Business Wire
Nov-14-14 01:04PM  EXELIXIS, INC. Financials EDGAR Online Financials
Nov-11-14 04:40PM  Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 Business Wire
Nov-06-14 06:00AM  Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma Business Wire
Nov-04-14 07:21PM  Exelixis tops 3Q profit forecasts AP
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today CCBN
04:16PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:14PM  Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer Business Wire
04:13PM  Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update Business Wire
04:02PM  EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q3 2014 Exelixis Inc Earnings Release - After Market Close CCBN
Nov-03-14 01:35PM  Will Exelixis (EXEL) Disappoint This Earnings Season? Zacks
Oct-16-14 05:16PM  EXELIXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Oct-15-14 04:10PM  EXELIXIS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Stateme EDGAR Online
Oct-14-14 04:12PM  Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014 Business Wire
Oct-03-14 08:50AM  Roche Presents Data on Cancer Immunotherapy Candidate Zacks
08:42AM  Exelixis (EXEL) Is in Oversold Territory: What's Next? Zacks
Sep-29-14 11:14AM  Cancer drug stocks on the move amid striking data at CNBC
09:19AM  Ahead of the Bell: Exelixis shares soar AP
03:00AM  Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
Sep-25-14 05:22PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Sep-18-14 06:43AM  Why Exelixis (EXEL) Stock Might be a Great Pick Zacks
Sep-17-14 01:00AM  Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress Business Wire
Sep-08-14 04:05PM  Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9 Business Wire
Sep-05-14 05:23PM  EXELIXIS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities EDGAR Online
08:55AM  Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte at TheStreet
Sep-04-14 08:06AM  Piramal, Exelixis And Novo Nordisk Research Woes Spell Doom For Drug Discovery Scientists at Forbes
Sep-03-14 06:14PM  Most active Nasdaq-traded stocks AP
09:40AM  Exelixis Slumps 55% on Disappointing Cabozantinib Results Zacks
08:40AM  Exelixis (EXEL) Enters Oversold Territory Zacks
Sep-02-14 12:25PM  Exelixis Plunges On Drug Trial Failure; Investors See Potential StockTwits -55.31%
10:40AM  S&P 500 flat after ISM data; Staples, Regeneron pop at MarketWatch
10:40AM  After the Exelixis Implosion, Is There Anything Left Ahead? at 24/7 Wall St.
10:21AM  Apple, Tesla hit intraday records; Conns falls at MarketWatch
10:01AM  Why Exelixis (EXEL) Stock Plunged to a One-Year Low Today at TheStreet
09:33AM  Exelixis Drug Fails Pivotal Prostate Cancer Study at TheStreet
09:24AM  Fight for Family Dollar heats up; Tesla powers ahead; Exelixis tanks Hot Stock Minute
09:10AM  Ahead of the Bell: Exelixis shares tumble AP
08:54AM  US STOCKS-Wall St set for flat open; manufacturing data on tap Reuters
08:20AM  Story Stocks from Briefing.com Briefing.com
08:14AM  Exelixis downgraded by Stifel Briefing.com
07:41AM  US STOCKS-Futures inch higher ahead of manufacturing data Reuters
Sep-01-14 07:02PM  Exelixis to cut jobs after prostate cancer drug fails late-stage study Reuters
06:00PM  Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer Business Wire
Aug-06-14 06:00AM  The R&D elite: America's most innovative companies at CNBC
Aug-01-14 09:45AM  Exelixis (EXEL) Showing Signs Of A Dead Cat Bounce Today at TheStreet
Jul-31-14 05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today CCBN -5.62%
04:17PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:13PM  Exelixis Announces Second Quarter 2014 Financial Results Business Wire
04:03PM  EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q2 2014 Exelixis, Inc. Earnings Release - After Market Close CCBN
Jul-25-14 09:50AM  Exelixis (EXEL) In A Perilous Reversal at TheStreet
06:34AM  Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session Zacks
Jul-22-14 05:02PM  Is this Exelixis Stock's Worst Nightmare? at Motley Fool
Jul-17-14 04:36PM  EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online -6.03%
01:08AM  Should Roche Buy Exelixis? at Motley Fool
Jul-16-14 04:05PM  Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014 Business Wire
10:04AM  Exelixis (EXEL) Showing Signs Of A Dead Cat Bounce Today at TheStreet
Jul-15-14 05:36PM  Time to Fall Back in Love With Exelixis Inc.? at Motley Fool -10.51%
05:18PM  Stocks finish mixed; Yellen's comments hurt biotech and social media shares Hot Stock Minute
10:33AM  Biotechs, social stocks weak after Yellen warning at CNBC
09:52AM  Exelixis (EXEL) Is Today's Perilous Reversal Stock at TheStreet
06:38AM  Exelixis (EXEL) Soars: Stock Adds 23% in Session Zacks
Jul-14-14 05:36PM  Up 23%: Time to Buy Exelixis? at Motley Fool +22.82%
04:40PM  Roche Presents Encouraging Data on Cobimetinib Zacks
04:24PM  Why the Exelixis Cancer Trial News Matters This Time 24/7 Wall St.
03:12PM  Why Exelixis (EXEL) Stock Is SpikingToday at TheStreet
02:18PM  Why Exelixis Inc. Stock Soared at Motley Fool
12:25PM  Exelixis Sees Success in Melanoma Treatment With Drug Combination at Minyanville
11:20AM  Exelixis seen as potential target for Roche, TheStreet says at theflyonthewall.com
11:14AM  Investor Believes Roche Buys Exelixis for Skin-Cancer Drug at TheStreet
07:46AM  Roche, Exelixis Skin Cancer Drug Delays Tumor Progression at TheStreet
02:47AM  Roche skin cancer drug meets main goal in combination study Reuters
01:00AM  Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
Jun-03-14 04:15PM  Exelixis to Present at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10 Business Wire
May-30-14 10:20AM  Why Wall Street Hates Exelixis Inc. at Motley Fool
May-29-14 05:06PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu EDGAR Online
May-23-14 06:32PM  Better Bad News Buy: Ariad Pharmaceuticals vs. Exelixis at Motley Fool
May-20-14 02:44PM  Exelixis' (EXEL) Presents at UBS Global Healthcare Conference (Transcript) at Seeking Alpha
May-16-14 06:48PM  Lightning Round: Wendy's, Hewlett-Packard, & More at CNBC
May-14-14 05:33PM  Cabozantinib and Cobimetinib to Be Featured in Ten Presentations at 2014 ASCO Annual Meeting Business Wire
May-13-14 06:34PM  Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha
May-08-14 04:16PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
May-07-14 01:00AM  Exelixis Announces Presentation of Final Phase 1b Data for Cobimetinib in Combination with Vemurafenib at EADO Congress 2014 Business Wire
May-06-14 04:19PM  Exelixis to Present at Two Investor Conferences in May Business Wire
May-01-14 10:57PM  Exelixis' CEO Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
07:28PM  Exelixis' Q1 Loss Widens 67% on Higher Trial and Personnel Costs at Motley Fool
05:00PM  Financial Results and Business Update Call scheduled for 5:00 pm ET today CCBN
04:55PM  Exelixis, Inc. Discusses Q1 2014 Results (Webcast) at Seeking Alpha
04:16PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:13PM  Exelixis Announces First Quarter 2014 Financial Results Business Wire
04:04PM  EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
09:02AM  Why You Should Watch Exelixis Inc., Geron Corporation and Vertex Pharmaceuticals Today at Motley Fool
Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaEVP and Chief Medical OfficerNov 15Option Exercise0.003,125078,730Nov 18 06:57 PM
Lamb PeterEVP, Discovery Research & CSONov 15Option Exercise0.002,083037,237Nov 18 06:55 PM
BURKE DEBORAHSVP & Chief Financial OfficerNov 15Option Exercise0.006,438019,377Nov 18 06:52 PM
MARCHESI VINCENT TDirectorSep 17Buy1.7120,00034,19945,000Sep 19 05:05 PM
Schwab GiselaEVP and Chief Medical OfficerFeb 15Option Exercise0.002,188071,494Feb 18 09:30 PM
KARBE FRANKEVP and CFOFeb 15Option Exercise0.001,954094,847Feb 18 09:31 PM
Lamb PeterEVP, Discovery Research & CSOFeb 15Option Exercise0.003,126035,743Feb 18 09:27 PM
SIMONTON PAMELA AEVP, ExelixisFeb 15Option Exercise0.001,875019,014Feb 18 09:28 PM
MORRISSEY MICHAELPresident and CEOFeb 15Option Exercise0.003,12503,125Feb 18 09:28 PM